PUBLISHER: DelveInsight | PRODUCT CODE: 1462302
PUBLISHER: DelveInsight | PRODUCT CODE: 1462302
"mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the mRNA-1345 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1345 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response.
In this case, the vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body's immune system recognize and protect itself if it encounters the virus. Therefore, one cannot become infected with RSV by receiving the investigational vaccine. The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+). Currently, the drug is in Phase III for older adults. mRNA-1345 is also ongoing in a Phase I trial in pediatric populations; RSV is also a large burden in the pediatric population.
RSV program has endorsed the start of the Phase III portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase II data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
mRNA-1345 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of mRNA-1345 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.